Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
Items 301–400 of 913
Regulation of neuronal autophagy and the implications in neurodegenerative diseases
Cai, Q., & Ganesan, D. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105582 · Cited by 75
Decline of striatal dopamine release in parkin‐deficient mice shown by ex vivo autoradiography
Sato, S., Chiba, T., Nishiyama, S., Kakiuchi, T., Tsukada, H., Hatano, T., Fukuda, T., Yasoshima, Y., Kai, N., Kobayashi, K., et al. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21032 · Cited by 71
“Goldberg et al. (2003) reported that DA actually increases extracellularly in knockout mice.”
BackgroundThe multi‐faceted role of mitochondria in the pathology of Parkinson’s disease
Trinh, D., Israwi, A. R., Arathoon, L. R., Gleave, J. A., & Nash, J. E. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15154 · Cited by 77
“…function to PD pathology and the involvement of Parkin in mitochondrial quality control, Parkin knockout mice and rats (at 24 and 8 months respectively), as well as Drosophila (at 3 weeks) do not show nigro-striatal neurodegeneration (Dave et al., 2014; Goldberg et al., 2003; Pesah et al., 2004).”
BackgroundThe Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis
Riparbelli, M. G., & Callaini, G. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.10.038 · Cited by 80
SUN, F., KANTHASAMY, A. G., ANANTHARAM, V., & KANTHASAMY, A. G. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.001 · Cited by 74
Pinto, M., Nissanka, N., & Moraes, C. T. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1384-17.2017 · Cited by 72
“On the other side, ParkinKO mice do not show typical signs of PD, including motor phenotypes, DA metabolism abnormalities, or nigrostriatal degeneration (Goldberg et al., 2003; Perez and Palmiter, 2005; Kitada et al., 2009).”
BackgroundMethodInfluentialExogenous -Synuclein Decreases Raft Partitioning of Cav2.2 Channels Inducing Dopamine Release
Ronzitti, G., Bucci, G., Emanuele, M., Leo, D., Sotnikova, T. D., Mus, L., Soubrane, C., Dallas, M. L., Thalhammer, A., Cingolani, L. A., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0608-14.2014 · Cited by 72
Thomas, B., von Coelln, R., Mandir, A. S., Trinkaus, D. B., Farah, M. H., Lim, K., Calingasan, N. Y., Beal, M. F., Dawson, V. L., & Dawson, T. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.021 · Cited by 76
Regulation of Parkin E3 ubiquitin ligase activity
Walden, H., & Martinez-Torres, R. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0978-5 · Cited by 77
Hermo, L., Pelletier, R. ‐., Cyr, D. G., & Smith, C. E. (2009) · Microscopy Research and Technique · doi:10.1002/jemt.20784 · Cited by 87
“Mice lacking PARKIN are fertile suggesting that PACRG is the cause of sterility in qkv males (Goldberg et al., 2003; Itier et al., 2003).”
Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons
Son, J. H., Kawamata, H., Yoo, M. S., Kim, D. J., Lee, Y. K., Kim, S., Dawson, T. M., Zhang, H., Sulzer, D., Yang, L., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03257.x · Cited by 74
Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity
Perez, F. A., Curtis, W. R., & Palmiter, R. D. (2005) · BMC Neuroscience · doi:10.1186/1471-2202-6-71 · Cited by 67
“Given the overwhelming evidence that mutations in parkin cause AR-JP in humans, it is surprising that mice with targeted deletions of parkin do not develop robust behavioral or pathological signs of parkinsonism [16-19].”
BackgroundResultVingill, S., Brockelt, D., Lancelin, C., Tatenhorst, L., Dontcheva, G., Preisinger, C., Schwedhelm‐Domeyer, N., Joseph, S., Mitkovski, M., Goebbels, S., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593585 · Cited by 67
“…PARK1/4 ( SNCA , a -synuclein), PARK8 (LRRK2), PARK2 (parkin), PARK6 (PINK1), or PARK7 (DJ-1) gene, which show little or no effect on mouse behavior and viability (Abeliovich et al , 2000; Goldberg et al , 2003; Kim et al , 2005; Gautier et al , 2008; Andres-Mateos et al , 2009; Tong et al , 2010).”
Disease modification in Parkinson's disease
Schapira, A. H. V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00769-0 · Cited by 75
Yamaguchi, A., Ishikawa, K.-I., Inoshita, T., Shiba-Fukushima, K., Saiki, S., Hatano, T., Mori, A., Oji, Y., Okuzumi, A., Li, Y., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.04.011 · Cited by 66
“However,mice harboring PARK2 or PARK6mutations do not reproduce the degeneration of midbrain dopaminergic neurons (Goldberg et al., 2003; Itier et al., 2003; Kitada et al., 2007).”
BackgroundEkholm-Reed, S., Goldberg, M. S., Schlossmacher, M. G., & Reed, S. I. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00535-13 · Cited by 66
“nullizygous mice (21) were backcrossed to the C57BL/6 background in the”
BackgroundMethodSelf-citationCebrián, C., Loike, J. D., & Sulzer, D. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_356 · Cited by 65
“Several groups have generated parkin KO mice (Goldberg et al. 2003; Itier et al. 2003; Von Coelln et al. 2004).”
BackgroundCrowley, E. K., Nolan, Y. M., & Sullivan, A. M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.11.003 · Cited by 76
Kurnik‐Łucka, M., Panula, P., Bugajski, A. J., & Gil, K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9818-6 · Cited by 65
“For example, parkin-deficient mice showed increased extracellular dopamine levels (measured quantitatively by in vivo microdialysis), likely due to an increase in dopamine release from nigral neurons (Goldberg et al. 2003) while striatal levels of dopamine and its major metabolites (measured by highperformance liquid…”
BackgroundResultInfluentialTokarew, J. M., Kodsi, D. N. E., Lengacher, N. A., Fehr, T. K., Nguyen, A., Shutinoski, B., O’Nuallain, B., Jin, M., Khan, J. M., Ng, A. C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02285-4 · Cited by 67
Efficient bi-allelic gene knockout and site-specific knock-in mediated by TALENs in pigs
Yao, J. T., Huang, J., Hai, T., Wang, X., Qin, G., Zhang, H., Wu, R., Cao, C., Xi, J., Yuan, Z., et al. (2014) · Scientific Reports · doi:10.1038/srep06926 · Cited by 64
Age related mitochondrial degenerative disorders in humans
Reeve, A. K., Krishnan, K. J., & Turnbull, D. M. (2008) · Biotechnology Journal · doi:10.1002/biot.200800066 · Cited by 64
“This study suggested that Parkin may have a role in the function of the nigrostriatal pathway but may also affect the regulation of dopamine within these neurons [42].”
BackgroundBaulac, S., LaVoie, M. J., Strahle, J. M., Schlossmacher, M. G., & Xia, W. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.06.014 · Cited by 74
Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease
Imbriani, P., Martella, G., Bonsi, P., & Pisani, A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105851 · Cited by 67
Viral Vector-Based Models of Parkinson’s Disease
der Perren, A. V., den Haute, C. V., & Baekelandt, V. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_310 · Cited by 80
“None of the parkin KO mice have substantial dopaminergic or behavioral abnormalities (Itier et al. 2003; Perez and Palmiter 2005; Von Coelln et al. 2004; Goldberg et al. 2003; Zhu et al. 2007).”
BackgroundKumar, P., Pradhan, K., Ramani, K., Ambasta, R. K., & Querfurth, H. W. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07588.x · Cited by 63
Genetic models of Parkinson disease
Lim, K., & Ng, C.-H. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.005 · Cited by 72
“17 mitochondrial respiration and antioxidant capacity, as well as increa sed ROS-mediated damage [77, 78, 84].”
BackgroundInfluentialThe Roles of Kinases in Familial Parkinson's Disease
Cookson, M., Dauer, W. T., Dawson, T. M., Fon, E. A., Guo, M., & Shen, J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3695-07.2007 · Cited by 71
“…activity of parkin (Hampe et al., 2006; Matsuda et al., 2006), and most candidate parkin substrates do not accumulate in the brains of parkin KO mice (Goldberg et al., 2003; Itier et al., 2003; Von Coelln et al., 2004; Ko et al., 2005; Perez and Palmiter, 2005; Periquet et al., 2005).”
BackgroundSelf-citationAre rodent models of Parkinson’s disease behaving as they should?
Vingill, S., Connor‐Robson, N., & Wade‐Martins, R. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.10.021 · Cited by 70
Parkinson's disease: from causes to mechanisms
Corti, O., Hampe, C., Darios, F. D., Ibáñez, P., Ruberg, M., & Brice, A. (2004) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2004.10.009 · Cited by 71
Saini, N., Oelhafen, S., Hua, H., Georgiev, O., Schaffner, W., & Büeler, H. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.011 · Cited by 61
Martin, L. J. (2007) · Reviews in the Neurosciences · doi:10.1515/revneuro.2007.18.2.115 · Cited by 62
Mouse Genetic Models of Human Brain Disorders
Leung, C., & Jia, Z. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00040 · Cited by 69
“Thus, LRRK2 mouse models have been shown to be a useful tool to understand the role of dopaminergic dysfunction in PD.”
BackgroundChakraborty, S., Bornhorst, J., Nguyen, T., & Aschner, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141123103 · Cited by 67
“dopamine (DA) concentration [115], while wildtype Parkin seems to increase cell surface expression of the dopamine transporter (DAT) and increase DA reuptake [116].”
BackgroundWatzlawik, J. O., Hou, X., Fricova, D., Ramnarine, C., Barodia, S. K., Gendron, T. F., Heckman, M. G., DeTure, M., Siuda, J., Wszolek, Z. K., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1834712 · Cited by 60
Self-citationBehavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism
Fleming, S. M., & Chesselet, M. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00004 · Cited by 63
“These alterations include increased extracellular striatal DA and reduced synaptic excitability in striatal medium spiny neurons (Goldberg et al., 2003) and inhibition of amphetamine-induced DA release, inhibition of glutamate transmission, and reduced DA transporter protein (Itier et al., 2003).”
BackgroundSelf-citationZabel, C., Šagi, D., Kaindl, A. M., Steireif, N., Kläre, Y., Mao, L., Peters, H., Wacker, M. A., KLEENE, R. B., & Klose, J. (2006) · Journal of Proteome Research · doi:10.1021/pr0601077 · Cited by 71
Wilkaniec, A., Lenkiewicz, A. M., Babiec, L., Murawska, E., Jęśko, H. M., Cieślik, M., Culmsee, C., & Adamczyk, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.591475 · Cited by 63
Anandhan, A., Nguyen, N., Syal, A., Dreher, L. A., Dodson, M. B., Zhang, D. D., & Madhavan, L. (2021) · Aging and Disease · doi:10.14336/ad.2021.0511 · Cited by 61
“Challenging Beam Task - Mice were subjected to a challenging beam task to test motor coordination and agility [31, 32].”
MethodParkinsonism following neuroleptic exposure: A double‐hit hypothesis?
Erro, R., Bhatia, K. P., & Tinazzi, M. (2015) · Movement Disorders · doi:10.1002/mds.26209 · Cited by 62
“Moreover, the behavioral profile of Parkin-null mice cannot be distinguished from that of control mice.(41) Hence, Parkinnull mice have been arguably considered a susceptibility model rather than a disease model.”
BackgroundSynaptic dysfunction in genetic models of Parkinson's disease: A role for autophagy?
Plowey, E. D., & Chu, C. T. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.011 · Cited by 59
“Deficiencies in presynaptic dopamine release in parkin knockout mice (Goldberg et al., 2003; Itier et al., 2003; Kitada et al., 2009) have driven research into presynaptic parkin substrates.”
Khasnavis, S., Ghosh, A., Roy, A., & Pahan, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.443556 · Cited by 64
“DJ1 mutations cause decreased resistance to oxidative stress in cells, flies, and mice (9).”
BackgroundBack and to the Future: From Neurotoxin‐Induced to Human Parkinson's Disease Models
Airavaara, M., Parkkinen, I., Konovalova, J., Albert, K., Chmielarz, P., & Domanskyi, A. (2020) · Current Protocols in Neuroscience · doi:10.1002/cpns.88 · Cited by 66
“Nigrostriatal dopamine system deficits have been observed in Parkin knockout mice without the loss of dopaminergic neurons up to 24 months of age (Goldberg et al., 2003; Itier et al., 2003).”
BackgroundHuynh, D. P., Nguyen, D., Pulst‐Korenberg, J., Brice, A., & Pulst, S.-M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.009 · Cited by 66
“The sensitivity of endogenous ataxin-2 to parkin levels is interesting as mice deficient for parkin failed to show any changes in the abundance of other known parkin interactors such as Pael-R and synphilin-1 (Goldberg et al., 2003; Palacino et al., 2004; Periquet et al., 2005).”
BackgroundHow do Parkin mutations result in neurodegeneration?
Imai, Y., & Takahashi, R. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.04.002 · Cited by 61
Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome
Riday, T. T., Dankoski, E. C., Krouse, M. C., Fish, E. W., Walsh, P. L., Han, J. E., Hodge, C. W., Wightman, R. M., Philpot, B. D., & Malanga, C. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61888 · Cited by 62
“Conversely, mice deficient in the E3 ubiquitin ligase parkin (Park2) exhibit increased striatal dopamine release while also showing decreases in both spontaneous and drug-stimulated locomotion without changes in dopaminergic cell number, striatal TH, or striatal dopamine content (32, 33).”
Parkin Is Protective against Proteotoxic Stress in a Transgenic Zebrafish Model
Fett, M. E., Pilsl, A., Paquet, D., van Bebber, F., Haass, C., Tatzelt, J., Schmid, B., & Winklhofer, K. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011783 · Cited by 65
“nigrostriatal dopaminergic neurons could not be found in different parkin knockout mouse strains with a targeted deletion of exon 2, 3 or 7 [6,8,9,49].”
BackgroundDopamine and α-synuclein dysfunction in Smad3 null mice
Tapia‐González, S., Giráldez‐Pérez, R. M., Cuartero, M. I., Casarejos, M. J., Mena, M. A., Wang, X., & Sánchez‐Capelo, A. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-72 · Cited by 61
“While in six independent parkin deficient mice generated there are no clear nigrostriatal deficits or common phenotypes, increased extracellular DA, decreased DAT, increased GSH levels and differences in the catabolism of DA have been described [48-50].”
BackgroundParkin in Parkinson’s Disease and Cancer: a Double-Edged Sword
Wahabi, K., Perwez, A., & Rizvi, M. M. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0879-1 · Cited by 60
“be restored with dopamine active transporter (DAT) inhibition [40].”
BackgroundRegulation and roles of mitophagy at synapses
Palikaras, K., & Tavernarakis, N. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111216 · Cited by 61
Tissue- and Cell-Specific Mitochondrial Defect in Parkin-Deficient Mice
Damiano, M., Gautier, C. A., Bulteau, A.-L., Ferrando-Miguel, R., Gouarne, C., Paoli, M. G., Pruss, R., Auchère, F., L'Hermitte-Stead, C., Bouillaud, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099898 · Cited by 57
“In some cases, including our model, moderate alterations in dopamine handling evocative of presymptomatic changes have been reported in the striatum, such as increased extracellular dopamine content, enhanced dopamine metabolism via monoamine oxidase and decreased motor activation following amphetamine-induced dopamin…”
BackgroundInfluentialWang, H., Imai, Y., Inoue, H., Kataoka, A., Iita, S., Nukina, N., & Takahashi, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05607.x · Cited by 58
Ari-1 Regulates Myonuclear Organization Together with Parkin and Is Associated with Aortic Aneurysms
Tan, K. L., Haelterman, N. A. T., Kwartler, C. S., Regalado, E. S., Lee, P.-T., Nagarkar-Jaiswal, S., Guo, D., Duraine, L., Wangler, M. F., Bamshad, M. J., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.03.020 · Cited by 59
“However, loss of PARK2 homologs have been associated with significant phenotypic discrepancies across species and even among cell types in the same organism (Pesah et al., 2004, Greene et al., 2003, Palacino et al., 2004, Goldberg et al., 2003, Von Coelln et al., 2004).”
BackgroundParkin does not prevent accelerated cardiac aging in mitochondrial DNA mutator mice
Woodall, B. P., Orogo, A. M., Najor, R. H., Cortez, M. Q., Moreno, E. R., Wang, H., Divakaruni, A. S., Murphy, A. N., & Gustafsson, Å. B. (2019) · JCI Insight · doi:10.1172/jci.insight.127713 · Cited by 56
Dysregulated Interorganellar Crosstalk of Mitochondria in the Pathogenesis of Parkinson’s Disease
Sironi, L., Restelli, L. M., Tolnay, M., Neutzner, A., & Frank, S. (2020) · Cells · doi:10.3390/cells9010233 · Cited by 57
Model fusion: The next phase in developing animal models for parkinson’s disease
Manning-Bog, A., & Langston, J. W. (2007) · Neurotoxicity Research · doi:10.1007/bf03033569 · Cited by 62
RING Finger Ubiquitin-Protein Isopeptide Ligase Nrdp1/FLRF Regulates Parkin Stability and Activity
Zhong, L., Tan, Y., Zhou, A., Yu, Q., & Zhou, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408955200 · Cited by 63
Mitochondrial dynamics and neuronal fate in Parkinson's disease
Santos, D., & Cardoso, S. M. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.05.002 · Cited by 63
Twenty years since the discovery of the parkin gene
Hattori, N., & Mizuno, Y. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1742-7 · Cited by 60
Circadian-based Treatment Strategy Effective in the BACHD Mouse Model of Huntington’s Disease
Whittaker, D. S., Loh, D. H., Wang, H. B., Tahara, Y., Kuljis, D. A., Cutler, T., Ghiani, C. A., Shibata, S., Block, G. D., & Colwell, C. S. (2018) · Journal of Biological Rhythms · doi:10.1177/0748730418790401 · Cited by 55
Lockhart, P. J., O’Farrell, C., & Farrer, M. J. (2004) · Movement Disorders · doi:10.1002/mds.20000 · Cited by 55
Mitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
Ebanks, B., & Chakrabarti, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.854321 · Cited by 62
A mutation in CLOCK leads to altered dopamine receptor function
Spencer, S., Torres‐Altoro, M. I., Falcon, E., Arey, R., Marvin, M., Goldberg, M., Bibb, J. A., & McClung, C. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07857.x · Cited by 54
Self-citationTransgenic rodent models of Parkinson’s disease
Harvey, B. K., Wang, Y., & Hoffer, B. J. (2009) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-211-78205-7_15 · Cited by 63
Aggregopathy in Neurodegenerative Diseases: Mechanisms and Therapeutic Implication
Dohm, C. P., Kermer, P., & Bähr, M. (2008) · Neurodegenerative Diseases · doi:10.1159/000119459 · Cited by 54
“), resulting in loss of dopaminergic neurons. However, parkin knockout mice do not display the expected neurodegeneration [”
BackgroundImpaired in vivo dopamine release in parkin knockout mice
Oyama, G., Yoshimi, K., Natori, S., Chikaoka, Y., Ren, Y., Funayama, M., Shimo, Y., Takahashi, R., Nakazato, T., Kitazawa, S., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.065 · Cited by 54
“Other studies also reported non-motor manifestations of PD (Zhu et al., 2007) and certain cognitive changes in PKOmice (Goldberg et al., 2003; Itier et al., 2003; Zhu et al., 2007).”
InfluentialOmura, T., Asari, M., Yamamoto, J., Oka, K., Hoshina, C., Maseda, C., Awaya, T., Tasaki, Y., Shiono, H., Yonezawa, A., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.131 · Cited by 53
Therapeutic targeting of mitophagy in Parkinson's disease
Masaldan, S., Callegari, S., & Dewson, G. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211107 · Cited by 51
McKeon, J. E., Di, S., Li, L., & Chin, L. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1781-2 · Cited by 60
“Consistent with a lack of Lewy bodies in ARJP patients, parkin mice show no protein aggregates in the brain [73, 74].”
The synaptic function of parkin
Sassone, J., Serratto, G. M., Valtorta, F., Silani, V., Passafaro, M., & Ciammola, A. (2017) · Brain · doi:10.1093/brain/awx006 · Cited by 52
“Increased spontaneous dopamine release from nigral neurons was found in parkin-knockout mice aged 8–9 months (Goldberg et al., 2003).”
BackgroundThe aggravating role of the ubiquitin–proteasome system in neurodegeneration
Ardley, H. C., Hung, C.-C., & Robinson, P. A. (2005) · FEBS Letters · doi:10.1016/j.febslet.2004.12.058 · Cited by 52
“geted ubiquitylation of these proteins with respect to PD remains largely unclear, since Parkin / mice display normal levels of a number of its known substrates [43].”
BackgroundThe proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1
Hol, E. M., van Leeuwen, F. W., & Fischer, D. F. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.09.001 · Cited by 53
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson’s disease
Romaní-Aumedes, J., Canal, M., Martín‐Flores, N., Sun, X., Pérez-Fernández, V., Wewering, S., Fernández‐Santiago, R., Ezquerra, M., Pont‐Sunyer, C., Lafuente, A., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.333 · Cited by 59
“These animals have motor and nonmotor behavioral impairments,(39) deficient synaptic transmission,(40) reduced mitochondrial respiration and increased oxidative damage,(41) and loss of DA neurons after 2 years of age.(42,43) The PaKO mice examined in our study were only 8month old.”
Hwang, C. J., Kim, Y., Son, D. J., Park, M. H., Choi, D., Park, P., Hellström, M., Han, S., Oh, K., Park, E., et al. (2016) · Redox Biology · doi:10.1016/j.redox.2016.12.008 · Cited by 52
“Likewise, similar mitochondrial defects were exhibited in Park2 knockout (KO) mouse models although only mice with conditional KO of Park2 recapitulate parkinsonian phenotype and striatonigral degeneration [14].”
Parkin absence accelerates microtubule aging in dopaminergic neurons
Cartelli, D., Amadeo, A., Calogero, A. M., Casagrande, F., Gregorio, C. D., Gioria, M., Kuzumaki, N., Costa, I., Sassone, J., Ciammola, A., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.010 · Cited by 52
Autophagy and LRRK2 in the Aging Brain
Albanese, F., Novello, S., & Morari, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01352 · Cited by 55
Value of genetic models in understanding the cause and mechanisms of Parkinson’s disease
Moore, D. J., & Dawson, T. M. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0045-7 · Cited by 50
Protein stability and aggregation in Parkinson's disease
Robinson, P. A. (2008) · Biochemical Journal · doi:10.1042/bj20080295 · Cited by 58
Inden, M., Kondo, J., Kitamura, Y., Takata, K., Nishimura, K., Taniguchi, T., Sawada, H., & Shimohama, S. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0040525 · Cited by 53
Yasuda, T., & Mochizuki, H. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0486-8 · Cited by 58
Chasing genes in Alzheimer?s and Parkinson?s disease
Bertoli‐Avella, A. M., Oostra, B. A., & Heutink, P. (2004) · Human Genetics · doi:10.1007/s00439-004-1097-7 · Cited by 54
Parkinson's disease: Exit toxins, enter genetics
Westerlund, M., Hoffer, B. J., & Olson, L. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.11.001 · Cited by 59
“resulting in a loss of Parkin function (Goldberg et al., 2003; Itier et al., 2003; von Coelln et al., 2004; Perez and Palmiter, 2005).”
BackgroundPINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates
Matsui, H., Gavinio, R., Asano, T., Uemura, N., Ito, H., Taniguchi, Y., Kobayashi, Y., Maki, T., Shen, J., Takeda, S., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt095 · Cited by 47
Self-citationLee, S., She, J., Deng, B., Kim, J.-J., de Andrade, M., Na, J., Sun, Z., Wampfler, J. A., Cunningham, J. M., Wu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9954 · Cited by 50
“Mouse strains were described previously [34, 47].”
Alam, G., Edler, M., Burchfield, S., & Richardson, J. R. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.03.008 · Cited by 48
“Transgenic mouse models of multiple genes involved in the development of PD such as alpha synuclein, Parkin, PINK, LRRK2, DJ-1 have been proven to be beneficial in the study of PD, but typically do not reproduce the full manifestation of PD phenotypes [5-11].”
Neuronal Mitophagy: Friend or Foe?
Doxaki, C., & Palikaras, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.611938 · Cited by 49
“However, PINK1 and Parkin deficiency does not trigger any severe PD-associated phenotype in mice, suggesting the existence of compensatory mitochondrial quality control mechanisms (Goldberg et al., 2003; Perez and Palmiter, 2005).”
BackgroundThe neurological mutant quaking viable is Parkin deficient
Lorenzetti, D., Antalffy, B. A., Vogel, H. S., Noveroske, J. K., Armstrong, D. L., & Justice, M. J. (2004) · Mammalian Genome · doi:10.1007/s00335-003-2333-5 · Cited by 57
“Recently, two independent studies reported the generation and phenotypic characterization of targeted mutations in the mouse Parkin gene (Goldberg et al. 2003; Itier et al. 2003).”
BackgroundInfluentialMetabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease
Saido, T. C. (2013) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.89.321 · Cited by 60
Smith, N. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00275 · Cited by 50
“Identification of GPR37L1 A year after the discovery of GPR37, Valdenaire et al. (1998) identified both GPR37 and a very highly related novel transcript encoding what they called ET(B)R-LP-2 (later termed GPR37L1), as part of a screen for ETB receptor homologs (Figure 1B).”
BackgroundTechniques for Motor Assessment in Rodents
Mann, A., & Chesselet, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00008-1 · Cited by 61
Self-citationMillichap, L. E., Damiani, E., Tiano, L., & Hargreaves, I. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111444 · Cited by 50
“PINK1 knockout (KO) Drosophila were found to have defects in mitochondrial morphology, including fragmented mitochondrial cristae, hypersensitivity to OS, MRC defects, and degeneration of dopaminergic neurons, which are mechanisms that have been suggested as contributing early on in the pathogenesis of PD [56,61,62].”
BackgroundZinc supplement greatly improves the condition of parkin mutant Drosophila
Saini, N., & Schaffner, W. (2010) · Biological Chemistry · doi:10.1515/bc.2010.052 · Cited by 47
MITOL promotes cell survival by degrading Parkin during mitophagy
Shiiba, I., Takeda, K., Nagashima, S., Ito, N., Tokuyama, T., Yamashita, S., Kanki, T., Komatsu, T., Urano, Y., Fujikawa, Y., et al. (2021) · EMBO Reports · doi:10.15252/embr.201949097 · Cited by 46
“Furthermore, in Parkin KO mice, the loss of dopaminergic neurons, which is a pathological hallmark of PD, was not observed (Goldberg et al , 2003; Itier et al , 2003; von Coelln et al , 2004; Perez & Palmiter, 2005).”
RNA metabolism and dysmyelination in schizophrenia
McInnes, L. A., & Lauriat, T. L. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.10.003 · Cited by 47
Life and Death Decisions—The Many Faces of Autophagy in Cell Survival and Cell Death
Yu, G., & Klionsky, D. J. (2022) · Biomolecules · doi:10.3390/biom12070866 · Cited by 52
Duplan, E., Sevalle, J., Viotti, J., Goiran, T., Bauer, C., Renbaum, P., Levy-Lahad, E., Gautier, C. A., Corti, O., Leroudier, N., et al. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt003 · Cited by 45
“Western blot analysis Parkin knockout murine brains have been recently described (Goldberg et al., 2003).”
MethodBrennan, L., Khoury, J., & Kantorow, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.020 · Cited by 47
Genetically modified large animal models for investigating neurodegenerative diseases
Yang, W., Chen, X., Li, S., & Li, X.-J. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00729-8 · Cited by 45
Genetic factors involved in the pathogenesis of Parkinson's disease
Lee, F. J. S., & Liu, F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.02.001 · Cited by 51
Moszczyńska, A., Saleh, J., Zhang, H., Vukusic, B., Lee, F. J. S., & Liu, F. (2007) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-0037-0 · Cited by 50
“Although many substrates have been identified, none of these (CDCrel-1, synphilin 1, α-Sp22, and α-SYN) were found to accumulate in the brains of parkin-null mice (Goldberg et al. 2003; Palacino et al. 2004).”
Background
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.